Latest News Archive
Please select Category, Year, and then Month to display items
29 March 2023
|
Story Samkelo Fetile
|
Photo Simba Matema
From left to right: Prof Jean Bernard Lekana-Douki, Director General at the CIRMF; Prof Francis Petersen, Rector and Vice-Chancellor of the UFS; and Prof Jean-Fabrice Yala, Scientific and Technical Director at the CIRMF.
The University of the Free State (UFS) recently welcomed senior members from the International Centre for Medical Research in Franceville (CIRMF), Gabon to sign a Memorandum of Understanding (MoU) between the two entities.
CIRMF is a non-profit medical research centre that was established in 1974. Its primary focus is on diagnosing infectious diseases that pose immediate problems in Gabon and the Central African sub-region. The centre is dedicated to improving public health through various initiatives, including the training of Gabonese health executives in doctoral and post-doctoral education.
“The signing of the MoU with CIRMF is a step in the right direction as the UFS continues to strengthen its footprint on the African Continent. This is seminal in driving the university’s internationalisation processes and opening an avenue to expanding research networks, especially in the African continent,” said Bonolo Makhalemele, Coordinator of strategic projects at the Office for International Affairs, UFS.
In the interest of developing broader research collaborations, the CIRMF delegation met with some UFS academics in a series of engagements, particularly in the Health Sciences Faculty and the Natural and Agricultural Sciences Faculty. “The integration of knowledge and practices that emanate from the continent provides opportunities for the co-creation of knowledge that can be shared with the rest of the world,” said Kagiso Ngake, Coordinator for Partnerships, Collaborative Degrees, and Outgoing Mobility at the Office for International Affairs, UFS.
A concrete roadmap was established to formalise the collaborations that resulted from these engagements and will commence as soon as April 2023. “We have laid a solid foundation and are on the way to a strong and rich partnership!” exclaimed Prof Jean Bernard Lekana-Douki, Director General at the CIRMF.
Prof Francis Petersen, Rector, and Vice-Chancellor of the UFS, further highlighted how the newly established partnership with the CIRMF aligns with the mandate of the UFS Vision 130 of expanding the UFS Africa research network.
Haemophilia home infusion workshop
2017-12-17
Parents receive training for homecare of their children with haemophilia.
Photo Supplied
Caregivers for haemophilia patients, and patients themselves from around the Free State and Northern Cape attended a home infusion workshop held by the Clinical Skills unit in the Faculty of Health Sciences in July 2017. “It felt liberating and I feel confident to give the factor to my son correctly,” said Amanda Chaba-Okeke, the mother of a young patient, at the workshop. Her son, also at the workshop, agreed. “It felt lovely and good to learn how to administer factor VIII.”
Clinical skills to empower parents and communities
There were two concurrent sessions: one attended by doctors from the Haemophilia Treatment Centre, and the other attended by community members including factor VIII and XI recipients, caregivers and parents. The doctors’ meeting was shown informative videos and demonstrations on how to administer the newly devised factor VII and XI kit, and discussed the pressing need for trained nurses at local clinics. Dr Jaco Joubert, a haematologist, made an educational presentation to the community members.
The South African Haemophilia Foundation was represented by Mahlomola Sewolane, who gave a brief talk about the role of the organisation in relation to the condition. Meanwhile, procedural training in the simulation laboratory involved doctors and nurses helping participants to learn the procedures by using mannequins and even some volunteers from among the patients.
A medical condition causing serious complications
Haemophilia is a medical condition in which the ability of the blood to clot is severely impaired, even from a slight injury. The condition is typically caused by a hereditary lack of a coagulation factor, most often factor VIII. Usually patients must go through replacement therapy in which concentrates of clotting factor VIII (for haemophilia A) or clotting factor IX (for haemophilia B) are slowly dripped or injected into the vein, to help replace the clotting factor that is missing or low. Patients have to receive this treatment in hospital.